Evidence map›Paper›PMID 27885273›Full record

ArticleLeukemia2017

Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.

F Yan, N Shen, J X Pang, Y W Zhang, E Y Rao, A M Bode, A Al-Kali, D E Zhang, M R Litzow, B Li and 1 more

Abstract read
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. The RNA NCell death & disease · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. The RNA NResearch square · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

F YanThe Hormel Institute, University of Minnesota, Austin, MN, USA.
N ShenThe Hormel Institute, University of Minnesota, Austin, MN, USA.
J X PangThe Hormel Institute, University of Minnesota, Austin, MN, USA.
Y W ZhangDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.
E Y RaoDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.
A M BodeThe Hormel Institute, University of Minnesota, Austin, MN, USA.
A Al-KaliHematology Division, Mayo Clinic, Rochester, MN, USA.
D E ZhangDepartment of Pathology, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
M R LitzowHematology Division, Mayo Clinic, Rochester, MN, USA.
B LiDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.
S J LiuThe Hormel Institute, University of Minnesota, Austin, MN, USA.
Hormel (United States) · USUniversity of Louisville · USMayo Clinic in Arizona · USUniversity of California, San Diego · USUniversity of Minnesota · US

Funding

Molecular Mechanism of Leukemogenesis Involving AML1-ETOR01CA104509 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · 2004 to 2025
$6.6M
Prevention of Breast Cancer Development by Epidermal Fatty Acid Binding Protein (R01CA180986 · NCI · UNIVERSITY OF MINNESOTA · PI LI, BING · 2014 to 2025
$3.3M
Targeting aberrant epigenetics by nanomedicineR01CA149623 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, SHUJUN · 2010 to 2014
$1.8M
The role of adipocyte/macrophage fatty acid binding protein in breast cancer deveR01CA177679 · NCI · UNIVERSITY OF MINNESOTA · PI LI, BING · 2014 to 2018
$1.6M
Bioactive compound modulation of epigenetic regulator Sp1/NFkB/miR network in AMLR21CA155915 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, SHUJUN · 2011 to 2012
$365k
Targeting high fat diet-driven DNA hypermethylation for AML chemopreventionR03CA186176 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, SHUJUN · 2016 to 2017
$155k
NCI NIH HHS R01 CA104509NCI NIH HHS R01 CA149623NCI NIH HHS R01 CA177679NCI NIH HHS R01 CA180986NCI NIH HHS R03 CA186176NCI NIH HHS R21 CA155915
6 · The paper itself

Abstract

Obesity is becoming more prevalent worldwide and is a major risk factor for cancer development. Acute myeloid leukemia (AML), the most common acute leukemia in adults, remains a frequently fatal disease. Here we investigated the molecular mechanisms by which obesity favors AML growth and uncovered the fatty acid-binding protein 4 (FABP4) and DNA methyltransferase 1 (DNMT1) regulatory axis that mediates aggressive AML in obesity. We showed that leukemia burden was much higher in high-fat diet-induced obese mice, which had higher levels of FABP4 and interleukin (IL)-6 in the sera. Upregulation of environmental and cellular FABP4 accelerated AML cell growth in both a cell-autonomous and cell-non-autonomous manner. Genetic disruption of FABP4 in AML cells or in mice blocked cell proliferation in vitro and induced leukemia regression in vivo. Mechanistic investigations showed that FABP4 upregulation increased IL-6 expression and signal transducer and activator of transcription factor 3 phosphorylation leading to DNMT1 overexpression and further silencing of the p15

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticAnimalsApoptosisCell ProliferationDiet, High-FatDNA (Cytosine-5-)-MethyltransferasesFatty Acid-Binding ProteinsHumansInterleukin-6Leukemia, Myeloid, AcuteMiceMice, Inbred C57BLObesitySTAT3 Transcription FactorTumor Cells, CulturedDNA (Cytosine-5-)-MethyltransferasesFABP4 protein, humanFatty Acid-Binding ProteinsInterleukin-6Stat3 protein, mouseSTAT3 Transcription Factor

Identifiers

PMID27885273
PMCPMC5457366
OpenAlexW2554898019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.